Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nasus PharmaNSRX -3.96%14 OCF Yield % is -14.43 as of Jul. 23, 2026. GuruFocus rates NSRX with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Nasus Pharma ranks worse than 89.25% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Nasus Pharma OCF Yield % Related Terms
Nasus Pharma OCF Yield % Historical Data
* Premium members only.
The historical data trend for Nasus Pharma's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Nasus Pharma's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nasus Pharma OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nasus Pharma's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Nasus Pharma's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nasus Pharma (NSRX) has a OCF Yield % of -14.43 as of Jul. 23, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Nasus Pharma and its competitors. According to the industry distribution chart, Nasus Pharma ranks #897 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 89.3%.
Is Nasus Pharma's OCF Yield % too high?
Nasus Pharma's current OCF Yield % is -14.43. Based on the distribution chart, Nasus Pharma ranks #897 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Nasus Pharma has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Nasus Pharma's OCF Yield % compare to MIRA and SCLX?
According to the Drug Manufacturers industry distribution chart, Nasus Pharma ranks #897 out of 1005 companies for OCF Yield %. This places Nasus Pharma in the lower half of its industry. The industry median OCF Yield % is 3.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.65, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Nasus Pharma and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nasus Pharma's current OCF Yield % is -14.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nasus Pharma stock overvalued right now?
Nasus Pharma (NSRX) has a current OCF Yield % of -14.43. The current OCF Yield % is -14.43. Nasus Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Nasus Pharma (NSRX), the current OCF Yield % is -14.43 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
14GF Score
Get the complete analysis for NSRX
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSRX has been successfully added to your 
